PUMA BIOTECHNOLOGY, INC. business relationships
Companies named in PUMA BIOTECHNOLOGY, INC.’s 10-K filed 2026-02-26, and public companies whose annual reports name PUMA BIOTECHNOLOGY, INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 70 / 100 Top 1% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in PUMA BIOTECHNOLOGY, INC.’s annual report 9
“The Pfizer Agreement originally stipulated that should we commercialize any of the compounds licensed from Pfizer or any products containing any of these compounds, we will be obligated to pay to Pfizer incremental annual royalties between approximately 10% and 20% of net sales of all such products,...” SEC filing
“The license is exclusive with respect to certain patent rights owned by or licensed to Pfizer.” SEC filing
“Should we commercialize additional compounds licensed from Pfizer or any products containing any of these compounds, we will be obligated to pay Pfizer annual royalties at a fixed rate in the low-to-mid teens of net sales of all such products, subject to certain reductions and offsets in some circum...” SEC filing
“Pursuant to our exclusive license agreement with Takeda, we are responsible for global development and commercialization of alisertib.” SEC filing
“While the drug candidates were developed by Pfizer, both the drug substance and drug product are manufactured by third -party contractors.” SEC filing
“While our drug candidates were developed by Pfizer and Takeda, both the drug substance and drug product are manufactured by third-party contractors.” SEC filing
“Our specialty distributor network sells to hospitals, physician practices and other sites of care and consists of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care.” SEC filing
“Our specialty distributor network sells to hospitals, physician practices and other sites of care and consists of McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care.” SEC filing
“On January 9, 2019, we entered into a sub-license agreement (the "Knight Agreement"), with Knight Therapeutics, Inc. ("Knight").” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.